Ann: Investor Presentation, page-33

OrthoATI

For Magnoman

Following the Biohorizon deal, OCC is in a far better position to negotiate; they are no longer deal takers but deal makers.

OrthoATI : Earlier announcement

The Company continues to progress its US plans with the evaluation of technology transfer options, FDA engagement and commercial preparation activities to prepare OrthoATI™ for a randomised controlled study under FDA supervision

controlled study under FDA supervision

Once these US plans are finalised, and the trial approved, they will have a definitive pathway to negotiate with J&J and other partners. OCC will be able to negotiate a far better-licensing agreement. It will make the Biohorizon deal look small.

Striate- Small deal but a company maker and ability to make the company cash flow positive in the medium term

Remplir - Sky is the limit

ATI - Fantastic product to broker a large licensing deal next year